Skip to main content
    X

    Xencor Inc (XNCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $35.40
    -1.69 (-4.56%)

    Market Cap: $2.78B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xencor Inc (XNCR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Xencor (XNCR) trades at 13.5x sales and 4.8x book value. Its P/S of 13.5x is above its 5-year median of 8.1x. Its forward P/E is 68.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E68.0x
    Price to sales13.5x
    Price to book4.8x
    PEGN/A
    FCF yield-6.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 16.4% above 11.6x and its P/B is 65.5% above 2.9x.

    MultipleCurrent5-year median10-year median
    P/S13.5x8.1x11.6x
    P/B4.8x2.1x2.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 29.7x in 2021 to 76.4x in 2019.

    Year endPriceP/EP/SP/B
    2025$15.31N/A9.0x1.8x
    2024$22.98N/A13.9x2.5x
    2023$21.23N/A7.3x2.0x
    2022$26.04N/A9.4x2.1x
    2021$40.1229.7x8.7x3.3x
    2020$43.63N/A20.4x4.4x
    2019$34.3976.4x12.4x3.3x
    2018$36.16N/A49.9x3.9x
    2017$21.92N/A22.2x3.7x
    2016$26.3247.0x10.0x3.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About XNCR

    What is XNCR's forward P/E ratio?

    Xencor has a forward P/E ratio of 68.0x.

    Is XNCR stock overvalued?

    GNG's valuation label for XNCR is Overvalued.

    What is XNCR's price to sales ratio?

    Xencor has a price to sales ratio of 13.5x.